An HIV vaccine could arrive sooner than we thought—using Moderna’s mRNA techhttps://www.msn.com/en-us/health/medical/an-hiv-vaccine-could-arrive-sooner-than-we-thought-e2-80-94using-moderna-e2-80-99s-mrna-tech/ar-BB1frKv2More than 60 years after the first known case of human HIV infection, and 40 years after the beginning of the deadly HIV/AIDS epidemic in the United States, a vaccine could be on the horizon.
In a Phase I Clinical trial that began in 2018, scientists at the International AIDS Vaccine Initiative (IAVI) and Scripps Research gave 48 participants two doses of either the vaccine candidate or a placebo, spaced two months apart. Results show that, in 97 percent of recipients, the vaccine stimulated the immune system to produce immunoglobulin G (IgG) B cells—a first step to making rare but powerful antibodies required to protect against various strains of HIV.
Now, IAVI and Scripps Research have announced they will continue building on the success of that first study by partnering with Moderna—the producers of the mRNA-1273 COVID-19 vaccine—to apply their mRNA-based technology to speed up the HIV vaccine’s development.
According to this chart,
https://www.modernatx.com/pipeline , Moderna has two HIV vaccine candidates in Preclinical (= before testing with humans) Development.
